Filing Details

Accession Number:
0001209191-23-007032
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-02-03 17:09:17
Reporting Period:
2023-02-01
Accepted Time:
2023-02-03 17:09:17
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1557746 Aclaris Therapeutics Inc. ACRS Pharmaceutical Preparations (2834) 460571712
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1604457 Neal Walker C/O Aclaris Therapeutics, Inc.
640 Lee Road, Suite 200
Wayne PA 19087
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2023-02-01 25,000 $16.75 1,180,763 No 4 S Direct
Common Stock Disposition 2023-02-02 1,079 $14.57 1,179,684 No 4 S Direct
Common Stock Disposition 2023-02-02 600 $15.55 1,179,084 No 4 S Direct
Common Stock Disposition 2023-02-02 3,121 $16.88 1,175,963 No 4 S Direct
Common Stock Disposition 2023-02-02 200 $17.54 1,175,763 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Footnotes
  1. These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 2, 2022.
  2. The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $16.28 to $17.14, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $14.25 to $15.22, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  4. The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $15.27 to $15.84, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote
  5. The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $16.51 to $17.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote
  6. The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $17.51 to $17.56, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote